Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
00187-5526-75 00187-5526 Bexarotene Targretin 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 29, 1999 In Use
00378-6955-01 00378-6955 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral July 9, 2015 In Use
68682-0003-10 68682-0003 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Dec. 17, 2015 In Use
16729-0023-01 16729-0023 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
16729-0023-10 16729-0023 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
47335-0485-88 47335-0485 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Dec. 15, 2014 In Use
54868-4503-00 54868-4503 Bicalutamide Casodex 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral June 4, 2002 In Use
54868-6133-00 54868-6133 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 9, 2010 In Use
60429-0177-01 60429-0177 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral May 8, 2014 In Use
60429-0177-05 60429-0177 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral May 8, 2014 In Use
60429-0177-30 60429-0177 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral May 8, 2014 In Use
60505-2642-01 60505-2642 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
60505-2642-03 60505-2642 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
63629-5321-01 63629-5321 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral April 24, 2014 In Use
63629-5321-02 63629-5321 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral April 24, 2014 In Use
63672-0005-00 63672-0005 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
67253-0191-03 67253-0191 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
67253-0191-10 67253-0191 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
63323-0136-10 63323-0136 Bleomycin Sulfate Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous Feb. 13, 2009 In Use
63323-0137-20 63323-0137 Bleomycin Sulfate Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous Feb. 13, 2009 In Use
55513-0160-01 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Dec. 18, 2014 In Use
63020-0049-01 63020-0049 Bortezomib Velcade 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 13, 2003 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug. 25, 2011 In Use
00574-0106-01 00574-0106 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 In Use
00574-0106-03 00574-0106 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 In Use
00781-5325-01 00781-5325 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 13, 1998 In Use
00781-5325-31 00781-5325 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 13, 1998 In Use
65841-0654-01 65841-0654 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 23, 2009 In Use
65841-0654-06 65841-0654 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 23, 2009 In Use
68382-0110-01 68382-0110 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 23, 2009 In Use
68382-0110-06 68382-0110 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 23, 2009 In Use
25021-0241-10 25021-0241 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous May 15, 2017 In Use
51817-0170-01 51817-0170 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous May 19, 2017 In Use
00093-7473-06 00093-7473 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2014 In Use
00093-7474-89 00093-7474 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2014 In Use
16714-0467-01 16714-0467 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
16714-0468-01 16714-0468 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
68083-0190-01 68083-0190 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 20, 2017 In Use
68083-0191-01 68083-0191 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 20, 2017 In Use
68083-0192-01 68083-0192 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 20, 2017 In Use
68083-0193-01 68083-0193 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 20, 2017 In Use
76075-0101-01 76075-0101 Carfilzomib Kyprolis 60.0 mg/30mL Chemotherapy Proteasome Inhibitor 20S Intravenous July 20, 2012 In Use
76075-0102-01 76075-0102 Carfilzomib Kyprolis 30.0 mg/15mL Chemotherapy Proteasome Inhibitor 20S Intravenous July 15, 2016 In Use
00703-5747-11 00703-5747 Cisplatin Cisplatin 50.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 1, 2000 In Use
00703-5748-11 00703-5748 Cisplatin Cisplatin 100.0 mg/100mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 1, 2000 In Use
16729-0288-11 16729-0288 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 13, 2016 In Use
16729-0288-38 16729-0288 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 13, 2016 In Use
44567-0509-01 44567-0509 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 In Use
44567-0510-01 44567-0510 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 13, 2012 In Use
44567-0511-01 44567-0511 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous April 15, 2015 In Use

Found 10,000 results in 10 millisecondsExport these results